Investor Letters
Bronte Capital — Amalthea Fund
- Amalthea Fund – October 2026 Amalthea Fund attributed October’s advance to Regeneron Pharmaceuticals, Visa and DSM Firmenich on the long side, despite pullbacks in Corteva and Alphabet. Broad gains across short positions in materials, technology, healthcare, industrials and energy also supported the result, while consumer cyclicals and financials detracted modestly. October 2026 —
- Amalthea Fund – September 2026 Amalthea tightened gross exposure and loss limits as correlations between its long and short books broke down amid the AI boom and rising bond-market stress. The fund argues that AI will disrupt employment and business models, while warning that automated analysis can create dangerous illusions of certainty, illustrated by its review of Bank BJB. third quarter 2026 BRK.A $1.3T
- Amalthea Fund – August 2026 Amalthea’s short book erased gains from its long holdings as sharp rallies in Basic Materials, Healthcare, Energy and Technology squeezed short positions. Interactive Brokers Group led long-side contributors, joined by Croda International, Regeneron Pharmaceuticals and Walt Disney, while Alphabet and Amazon detracted. August 2026 —
- Amalthea Fund – July 2026 Amalthea Fund is trimming Alphabet despite admiring its AI pivot, judging that disruption of Google Search and enormous capital spending leave the stock unusually difficult to value. The portfolio has also reduced small Japanese AI-chain winners while seeking short opportunities among non-AI-adjacent speculative companies. July 2026 GOOGL $3.5TMU $814BSKHY $929B